PharmacoEconomics & Outcomes News

, Volume 818, Issue 1, pp 20–20 | Cite as

Niraparib cost effective for recurrent ovarian cancer?

Clinical study

Niraparib appears to be more cost effective than olaparib for maintenance therapy in patients with recurrent ovarian cancer (OC), but neither poly-ADP ribose polymerase (PARP) inhibitor may be cost effective in patients without deleterious germline BRCA (gBRCA) mutations, according to findings of two US studies.

OC with and without gBRCA mutations

Niraparib appears to be cost effective compared with olaparib, rucaparib or routine surveillance (RS) for maintenance treatment of recurrent OC in patients with gBRCA mutations, say authors of a TESARO-funded study published in PharmacoEconomics.1

A decision-analytic model populated with data from a phase III niraparib study (ENGOT-OV16/NOVA) and trials of rucaparib (ARIEL3) and olaparib (Study 19) was used to evaluate the cost effectiveness of niraparib versus olaparib, rucaparib and RS, in patients with recurrent OC with and without gBRCA mutations, from a US healthcare payer perspective over a lifetime time horizon.

Niraparib was estimated...


  1. 1.
    Guy H, et al. Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States. PharmacoEconomics : 27 Nov 2018. Available rom: URL: Scholar
  2. 2.
    Zhong L, et al. Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer. Journal of Managed Care and Specialty Pharmacy 24: 1219-1228, No. 12, Dec 2018. Available from: URL: Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations